Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.0	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.0	0.547	0.01	NA	NA	0.547
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.0	0.604	0.01	-3.02	1.0	0.621
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
Hs 578T	ZSTK474	3		sigmoid	sigmoid	Hs578T ZSTK474 3	8	2.863	0.913	0.31	0.201	0.613	0.143	0.846	0.999	6.21e-10	NA	0.607	0.298	0.767	0.329	0.211	0.895	0.999	1.43e-09	NA
Hs 578T	GDC-0980	3		sigmoid	sigmoid	Hs578T apitolisib 3	8	2.831	0.243	0.145	0.315	0.19	0.112	1.02	0.998	4.02e-09	NA	0.179	0.206	0.665	0.114	0.196	1.09	0.999	9.76e-10	NA
Hs 578T	PI103	2		sigmoid	sigmoid	Hs578T PI-103 2	8	2.503	0.223	-0.0213	0.356	0.303	-0.15	0.858	0.999	7.33e-10	NA	0.206	0.167	0.661	0.152	0.121	0.921	0.999	1.9e-09	NA
Hs 578T	AZD8055	2		sigmoid	sigmoid	Hs578T AZD8055 2	8	2.480	0.0521	0.149	0.469	0.0387	0.142	1.13	0.999	3.49e-10	NA	0.0495	0.253	0.557	0.0273	0.249	1.16	0.999	4.45e-10	NA
HCC1806	Buparlisib	3	72	sigmoid	sigmoid	HCC1806 buparlisib 0 3 72	8	3.195	0.808	-0.257	0.203	0.96	-0.303	2.74	1.0	2.03e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
Hs 578T	WYE-125132	1		sigmoid	sigmoid	Hs578T WYE-132 1	8	2.015	0.0322	0.0601	0.551	0.0286	0.0544	0.962	0.998	4.17e-09	NA	0.0469	0.278	0.55	0.0207	0.275	0.978	0.999	2.33e-09	NA
HCC1806	Buparlisib	1	72	sigmoid	sigmoid	HCC1806 buparlisib 0 1 72	8	2.742	0.748	-0.369	0.226	0.931	-0.415	2.75	1.0	2.95e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC38	Torin1	3	72	sigmoid	sigmoid	HCC38 Torin1 0 3 72	8	1.441	0.0231	-0.202	0.666	0.0412	-0.248	0.698	0.999	5.79e-10	NA	0.0787	0.266	0.572	0.0306	0.245	0.714	0.999	5.55e-10	NA
HCC1806	Buparlisib	2	72	sigmoid	sigmoid	HCC1806 buparlisib 0 2 72	8	2.827	0.759	-0.346	0.221	0.937	-0.392	2.75	1.0	2.72e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
BT-549	GDC-0980	1	72	sigmoid	sigmoid	BT549 apitolisib 0 1 72	8	1.781	0.19	0.113	0.333	0.16	0.1	1.27	0.999	4.05e-10	NA	0.328	0.352	0.744	0.132	0.347	1.31	0.999	7.05e-10	NA
HCC38	BX-912	1	72	sigmoid	sigmoid	HCC38 BX-912 0 1 72	8	1.760	0.529	-0.322	0.274	0.591	-0.322	4.49	0.999	1.36e-10	NA	0.584	0.149	0.818	0.541	0.149	4.63	0.999	8.39e-10	NA
Hs 578T	Torin1	2		sigmoid	sigmoid	Hs578T Torin1 2	8	2.548	0.0205	0.144	0.566	0.0148	0.14	1.0	0.999	3.13e-10	NA	0.0182	0.241	0.463	0.00975	0.24	1.04	0.999	6.11e-10	NA
Hs 578T	WYE-125132	2		sigmoid	sigmoid	Hs578T WYE-132 2	8	2.544	0.0374	0.152	0.505	0.0268	0.147	1.04	0.999	8.81e-10	NA	0.0344	0.246	0.516	0.0183	0.239	1.03	0.999	2.53e-09	NA
BT-549	Torin1	1	72	sigmoid	sigmoid	BT549 Torin1 0 1 72	8	1.794	0.017	0.0603	0.621	0.0151	0.056	0.976	0.998	7.25e-09	NA	0.0333	0.32	0.532	0.0118	0.316	0.966	0.998	9.27e-09	NA
Hs 578T	GDC-0980	2		sigmoid	sigmoid	Hs578T apitolisib 2	8	2.520	0.176	-0.0558	0.391	0.275	-0.201	0.758	0.997	3.91e-08	NA	0.159	0.151	0.627	0.121	0.1	0.818	0.998	1.45e-08	NA
HCC38	WYE-125132	3	72	sigmoid	sigmoid	HCC38 WYE-132 0 3 72	8	1.449	0.0494	-0.0216	0.518	0.0504	-0.0117	1.18	0.998	9.69e-09	NA	0.128	0.355	0.662	0.0441	0.361	1.2	0.998	9.53e-09	NA

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)